Supplementary Table S4 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Ingenuity IGS-18 pathway analysis.创新性 IGS-18 通路分析。